Marta Rybczynski

Conference Coverage

Designing Patient-Centered Pathways at Kaiser Permanente

10/02/2021

Mishellene McKinney, MHA, RN, OCN, discusses how Kaiser Permanente is using Human Centered Design to inform cancer care delivery and survivorship pathway design.

Mishellene McKinney, MHA, RN,...

10/02/2021

Clinical Pathways

Conference Coverage

Addressing Disparities in Cancer Health, Equity, and Outcomes

03/29/2022

Marta Rybczynski ;

A panel at the 2022 Community Oncology Conference discussed how their programs address disparities in cancer care and access to cancer care.

A panel at the 2022 Community...

03/29/2022

Journal of Clinical Pathways

News

Comparing Consolidation and Maintenance vs Maintenance Alone for Newly Diagnosed MM

11/08/2021

Marta Rybczynski ;

Consolidation treatment with bortezomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance may improve PFS for newly diagnosed MM, compared to maintenance alone.

Consolidation treatment with...

11/08/2021

Journal of Clinical Pathways

Conference Coverage

Factors Predicting the Likelihood of Undergoing Biomarker Testing in Ovarian Cancer

06/08/2022

Marta Rybczynski ;

According to findings presented at ASCO 2022, only 55% of patients with ovarian cancer underwent biomarker testing due to factors such as insurance type, ECOG status, and region.

According to findings presented...

06/08/2022

Journal of Clinical Pathways

News

Cost Analysis of Intravenous vs Subcutaneous Rituximab for Patients With NHL

02/18/2022

Marta Rybczynski ;

Study findings suggest a 20% transition from intravenous to subcutaneous rituximab for patients with NHL has the potential to generate significant US health system value in the form of payer savings, increased practice capacity, and patient...

Study findings suggest a 20%...

02/18/2022

Journal of Clinical Pathways

Conference Coverage

Treatment Preferences for Relapsed/Refractory MM in Later Lines of Therapy

10/07/2021

Marta Rybczynski ;

Findings from a recent study revealed that oncologists place higher relative importance on OS, PFS, and ORR, and prefer a decreased risk of grade 3/4 keratopathy and thrombocytopenia when choosing later line therapies in relapsed/refractory...

Findings from a recent study...

10/07/2021

Journal of Clinical Pathways

Conference Coverage

Praise, Challenges, and Outcomes of The Oncology Medical Home Certification Pilot

03/31/2022

Marta Rybczynski ;

A panel at the 2022 Community Oncology Conference discussed the building and implementation of the ASCO and COA Oncology Medical Home Model, touching on its quality, outcomes, and value in cancer care.

A panel at the 2022 Community...

03/31/2022

Journal of Clinical Pathways

News

Real-World Cardiovascular Adverse Events Associated With ICIs in the United States

11/16/2021

Marta Rybczynski ;

Study findings the importance of risk stratification and cardiovascular monitoring for patients with cancer receiving immune checkpoint inhibitor therapy.

Study findings the importance of...

11/16/2021

Journal of Clinical Pathways

Conference Coverage

BRCA Variants in Patients With Ovarian Cancer and the Risk of Adverse Reactions

06/10/2022

Marta Rybczynski ;

A real-world study presented at the 2022 ASCO Annual Meeting found that BRCA variants may not increase the risk of adverse reactions among patients with ovarian cancer.

A real-world study presented at...

06/10/2022

Journal of Clinical Pathways

News

Interventions Improve Symptom Controllability Among Patients With Recurrent Ovarian Cancers

02/24/2022

Marta Rybczynski ;

Study findings revealed the web-based WRITE Symptoms interventions significantly improved symptom controllability for patients with ovarian cancer, regardless of delivery method.

Study findings revealed the...

02/24/2022

Journal of Clinical Pathways